RT Journal Article
SR Electronic
T1 Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.09.20148429
DO 10.1101/2020.07.09.20148429
A1 Seow, Jeffrey
A1 Graham, Carl
A1 Merrick, Blair
A1 Acors, Sam
A1 Steel, Kathyrn J.A.
A1 Hemmings, Oliver
A1 O’Bryne, Aoife
A1 Kouphou, Neophytos
A1 Pickering, Suzanne
A1 Galao, Rui Pedro
A1 Betancor, Gilberto
A1 Wilson, Harry D.
A1 Signell, Adrian W.
A1 Winstone, Helena
A1 Kerridge, Claire
A1 Temperton, Nigel
A1 Snell, Luke
A1 Bisnauthsing, Karen
A1 Moore, Amelia
A1 Green, Adrian
A1 Martinez, Lauren
A1 Stokes, Brielle
A1 Honey, Johanna
A1 Izquierdo-Barras, Alba
A1 Arbane, Gill
A1 Patel, Amita
A1 O’Connell, Lorcan
A1 O’Hara, Geraldine
A1 MacMahon, Eithne
A1 Douthwaite, Sam
A1 Nebbia, Gaia
A1 Batra, Rahul
A1 Martinez-Nunez, Rocio
A1 Edgeworth, Jonathan D.
A1 Neil, Stuart J.D.
A1 Malim, Michael H.
A1 Doores, Katie J
YR 2020
UL http://medrxiv.org/content/early/2020/07/11/2020.07.09.20148429.abstract
AB Antibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 days following the onset of COVID-19 symptoms. However, due to the recent emergence of this virus in the human population it is not yet known how long these Ab responses will be maintained or whether they will provide protection from re-infection. Using sequential serum samples collected up to 94 days post onset of symptoms (POS) from 65 RT-qPCR confirmed SARS-CoV-2-infected individuals, we show seroconversion in >95% of cases and neutralizing antibody (nAb) responses when sampled beyond 8 days POS. We demonstrate that the magnitude of the nAb response is dependent upon the disease severity, but this does not affect the kinetics of the nAb response. Declining nAb titres were observed during the follow up period. Whilst some individuals with high peak ID50 (>10,000) maintained titres >1,000 at >60 days POS, some with lower peak ID50 had titres approaching baseline within the follow up period. A similar decline in nAb titres was also observed in a cohort of seropositive healthcare workers from Guy’s and St Thomas’ Hospitals. We suggest that this transient nAb response is a feature shared by both a SARS-CoV-2 infection that causes low disease severity and the circulating seasonal coronaviruses that are associated with common colds. This study has important implications when considering widespread serological testing, Ab protection against re-infection with SARS-CoV-2 and the durability of vaccine protection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKing's Together Rapid COVID-19 Call awards to MHM, KJD, SJDN and RMN. MRC Discovery Award MC/PC/15068 to SJDN, KJD and MHM. AWS and CG were supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1). GB was supported by the Wellcome Trust (106223/Z/14/Z to MHM). SA was supported by an MRC-KCL Doctoral Training Partnership in Biomedical Sciences industrial Collaborative Award in Science & Engineering (iCASE) in partnership with Orchard Therapeutics (MR/R015643/1). NK was supported by the Medical Research Council (MR/S023747/1 to MHM). SP HDW and SJDN were supported by a Wellcome Trust Senior Fellowship (WT098049AIA). Fondation Dormeur, Vaduz for funding equipment (to KJD). Development of SARS-CoV-2 reagents (RBD) was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Work was undertaken in accordance with the UK Policy Framework for Health and Social Care Research and approved by the Risk and Assurance Committee at Guy's and St Thomas' NHS Foundation Trust (GSTFT). Serum was collected from consenting healthcare workers with expedited approval from GSTFT Research & Development office, Occupational Health department and Medical director.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data was used in this study and is not available for distribution outside the host organisations.